Shots:

• Mimetas is eligible to receive up front and milestones while Roche will get an option to exclusively license specific disease models and assays for use in drug discovery in IBD and HBV infections
• Mimetas will be responsible for developing tissue-based disease models and assays in the OrganoPlate that help to increases the predictability of biomarkers and reduces animal use in scientific testing. Roche will obtain access to technology- disease models- and scientific results
• The collaboration enables research & early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV

­ Ref: Mimetas | Image: Roche